Recognition Health

Re:Cognition Health is a leading global provider of brain and mind healthcare, specializing in the early diagnosis, treatment, and care of individuals with cognitive impairment, neurodegenerative diseases, and mental health concerns. Founded in 2011, the company operates a transatlantic network of specialized clinics and clinical trial centers across the United Kingdom, the United States, and Ireland. Re:Cognition Health is a major partner for global pharmaceutical companies and contract research organizations (CROs), conducting advanced Phase 2 and Phase 3 clinical trials for groundbreaking treatments in Alzheimer's disease, dementia, ADHD, autism, and traumatic brain injury. Notably, the company has been a key clinical site for major Alzheimer's trials, including those for the FDA-approved disease-modifying therapies Leqembi (lecanemab) and Kisunla (donanemab).